Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
<p>Abstract</p> <p>Background</p> <p>The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2012-02-01
|
| Serie: | BMC Urology |
| Accesso online: | http://www.biomedcentral.com/1471-2490/12/3 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|